PMC:7696151 / 23733-24029 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"703","span":{"begin":257,"end":265},"obj":"Species"},{"id":"712","span":{"begin":107,"end":127},"obj":"Chemical"},{"id":"713","span":{"begin":158,"end":167},"obj":"Chemical"},{"id":"714","span":{"begin":203,"end":206},"obj":"Chemical"},{"id":"715","span":{"begin":269,"end":274},"obj":"Chemical"}],"attributes":[{"id":"A703","pred":"tao:has_database_id","subj":"703","obj":"Tax:9606"},{"id":"A713","pred":"tao:has_database_id","subj":"713","obj":"MESH:D012254"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"MESH:D006886"},{"id":"A715","pred":"tao:has_database_id","subj":"715","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"into two groups; the control group treated with standard-of-care (SOC) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC. At the end of the treatment (12 weeks), patients of HCQ + SOC group showed a hi"}